EUR-1100 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
98	Eosinophilic gastrointestinal disease	2

98. Eosinophilic gastrointestinal disease

---

Clinical trials : 172 /  Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01498497 (ClinicalTrials.gov)	January 2012	16/12/2011	A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021	Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects]	Eosinophilic Esophagitis	Drug: EUR-1100;Drug: Placebo	Forest Laboratories	NULL	Completed	12 Years	55 Years	All	14	Phase 1/2	United States
2	NCT01386112 (ClinicalTrials.gov)	September 2011	28/6/2011	Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis	A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE)	Eosinophilic Esophagitis	Drug: EUR-1100;Drug: placebo	Aptalis Pharma	NULL	Completed	12 Years	55 Years	Both	24	Phase 1/Phase 2	United States